A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

You may not be if

• Patient has a documented hormone (estrogen and/or progesterone) receptor expression and lack of HER2 receptor overexpression or lack of HER2 gene amplification (HR+/HER2- breast cancer subtype)
• Patient had no prior treatment for advanced breast cancer
• Patient has no symptomatic metastases to the central nervous system
• There is no other malignancies in patient requiring active treatment
• Patient is without co-occurring other malignancies treated with palliative assumption
• Parallel patient's participation in any other clinical trial at the time when the decision over the advanced breast cancer treatment was made or up to 30 days before it.